score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.1395	86.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	KIRC_CONSENSUS2	TCGA-CJ-6033-01A-11D-1669-08	TCGA-CJ-6033-11A-01D-1669-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047L	0.3468	124.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047L (Missense)	1	KIRC_CONSENSUS2	TCGA-BP-4960-01A-01D-1462-08	TCGA-BP-4960-11A-01D-1462-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.G1049R	0.2899	138.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.G1049R (Missense)	1	KIRC_CONSENSUS2	TCGA-A3-3357-01A-02D-1421-08	TCGA-A3-3357-11A-01D-1421-08
Putatively Actionable			Guideline	Somatic Variant	SF3B1	Missense	p.G742D	0.1831	71.0	0.0	0.0																Putatively Actionable	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.G742D (Missense)		KIRC_CONSENSUS2	TCGA-B0-5698-01A-11D-1669-08	TCGA-B0-5698-10A-01D-1669-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.Y82N	0.3	260.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.Y82N (Missense)	1	KIRC_CONSENSUS2	TCGA-A3-A8OV-01A-11D-A36X-10	TCGA-A3-A8OV-10A-01D-A370-10
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.H805R	0.2807	114.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.H805R (Missense)	1	KIRC_CONSENSUS2	TCGA-B0-5713-01A-11D-1669-08	TCGA-B0-5713-11A-01D-1669-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.S1042N	0.3206	209.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.S1042N (Missense)	1	KIRC_CONSENSUS2	TCGA-B0-5116-01A-02D-1421-08	TCGA-B0-5116-11A-01D-1421-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH2	Missense	p.A214V	0.0919	185.0	0.0	0.0		Investigate Actionability	Enasidenib	IDH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.	Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf								Investigate Actionability	0	More frequent in Acute Myeloid Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					IDH2 p.A214V (Missense)		KIRC_CONSENSUS2	TCGA-BP-4795-01A-02D-1421-08	TCGA-BP-4795-11A-01D-1421-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Missense	p.K6M	0.1243	555.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					EZH2 p.K6M (Missense)		KIRC_CONSENSUS2	TCGA-B8-5163-01A-01D-1421-08	TCGA-B8-5163-10A-01D-1421-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.G637W	0.2424	33.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.G637W (Missense)		KIRC_CONSENSUS2	TCGA-CJ-4908-01A-01D-1429-08	TCGA-CJ-4908-11A-01D-1429-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.V242L	0.3374	412.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.V242L (Missense)	0	KIRC_CONSENSUS2	TCGA-CZ-5467-01A-01D-1501-10	TCGA-CZ-5467-11A-01D-1501-10
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.F889V	0.307	228.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.F889V (Missense)	0	KIRC_CONSENSUS2	TCGA-CJ-5680-01A-11D-1534-10	TCGA-CJ-5680-11A-01D-1535-10
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.P937A	0.182	467.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.P937A (Missense)	0	KIRC_CONSENSUS2	TCGA-CZ-5466-01A-01D-1501-10	TCGA-CZ-5466-11A-01D-1501-10
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.D1026E	0.3856	153.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.D1026E (Missense)	0	KIRC_CONSENSUS2	TCGA-CW-5585-01A-01D-1534-10	TCGA-CW-5585-11A-01D-1535-10
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.E1030D	0.2564	156.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.E1030D (Missense)	0	KIRC_CONSENSUS2	TCGA-B0-5121-01A-02D-1421-08	TCGA-B0-5121-11A-01D-1421-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.A59G	0.1037	270.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.A59G (Missense)	1	KIRC_CONSENSUS2	TCGA-B0-5400-01A-01D-1501-10	TCGA-B0-5400-11A-01D-1501-10
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Nonsense	p.R250*	0.2989	542.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.R250* (Nonsense)		KIRC_CONSENSUS2	TCGA-B0-5703-01A-11D-1534-10	TCGA-B0-5703-11A-01D-1534-10
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Frameshift	p.S496Ifs*16	0.1717	198.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.S496Ifs*16 (Frameshift)		KIRC_CONSENSUS2	TCGA-B0-5097-01A-01D-1421-08	TCGA-B0-5097-11A-01D-1421-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Frameshift	p.K750Sfs*3	0.3137	102.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.K750Sfs*3 (Frameshift)		KIRC_CONSENSUS2	TCGA-CZ-5986-01A-11D-1669-08	TCGA-CZ-5986-11A-01D-1669-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Frameshift	p.A886Kfs*12	0.1374	262.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.A886Kfs*12 (Frameshift)		KIRC_CONSENSUS2	TCGA-BP-4801-01A-02D-1421-08	TCGA-BP-4801-11A-01D-1421-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Splice Site	p.X1370_splice	0.2245	196.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.X1370_splice (Splice Site)		KIRC_CONSENSUS2	TCGA-A3-3317-01A-01D-0966-08	TCGA-A3-3317-11A-01D-0966-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Frameshift	p.Q2066Rfs*16	0.2875	80.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.Q2066Rfs*16 (Frameshift)		KIRC_CONSENSUS2	TCGA-BP-5009-01A-01D-1462-08	TCGA-BP-5009-11A-01D-1462-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Nonsense	p.R2419*	0.2714	70.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.R2419* (Nonsense)		KIRC_CONSENSUS2	TCGA-CJ-5686-01A-11D-1669-08	TCGA-CJ-5686-11A-01D-1669-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Nonsense	p.R2580*	0.2121	132.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.R2580* (Nonsense)		KIRC_CONSENSUS2	TCGA-B0-5097-01A-01D-1421-08	TCGA-B0-5097-11A-01D-1421-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Frameshift	p.T2640Lfs*6	0.3423	298.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.T2640Lfs*6 (Frameshift)		KIRC_CONSENSUS2	TCGA-CZ-5451-01A-01D-1501-10	TCGA-CZ-5451-11A-01D-1501-10
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.E3A	0.4	150.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.E3A (Missense)	1	KIRC_CONSENSUS2	TCGA-A3-A8OV-01A-11D-A36X-10	TCGA-A3-A8OV-10A-01D-A370-10
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.S407L	0.193	114.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.S407L (Missense)		KIRC_CONSENSUS2	TCGA-B4-5832-01A-11D-1669-08	TCGA-B4-5832-10A-01D-1669-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.R490H	0.1087	92.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.R490H (Missense)		KIRC_CONSENSUS2	TCGA-B2-4101-01A-02D-1458-08	TCGA-B2-4101-11A-01D-1458-08
Investigate Actionability	Clinical evidence			Somatic Variant	FLCN	Frameshift	p.F417Sfs*51	0.3333	27.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Wagle N, Grabiner BC, Van allen EM, et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med. 2014;371(15):1426-33.	https://doi.org/10.1056/NEJMoa1403352																	FLCN p.F417Sfs*51 (Frameshift)		KIRC_CONSENSUS2	TCGA-BP-4961-01A-01D-1462-08	TCGA-BP-4961-11A-01D-1462-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.V219I	0.2958	142.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.V219I (Missense)		KIRC_CONSENSUS2	TCGA-B0-5110-01A-01D-1421-08	TCGA-B0-5110-11A-01D-1421-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.S649T	0.3889	144.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.S649T (Missense)		KIRC_CONSENSUS2	TCGA-A3-3385-01A-02D-1421-08	TCGA-A3-3385-11A-01D-1421-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.E1687Kfs*?	0.4658	219.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.E1687Kfs*? (Frameshift)		KIRC_CONSENSUS2	TCGA-CJ-5683-01A-11D-1534-10	TCGA-CJ-5683-11A-01D-1535-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.S1607Qfs*5	0.3373	166.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.S1607Qfs*5 (Frameshift)		KIRC_CONSENSUS2	TCGA-CJ-5675-01A-11D-1534-10	TCGA-CJ-5675-11A-01D-1534-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.F1594Lfs*2	0.6067	89.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.F1594Lfs*2 (Frameshift)		KIRC_CONSENSUS2	TCGA-BP-5185-01A-01D-1429-08	TCGA-BP-5185-11A-01D-1429-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.L1564Wfs*32	0.6571	140.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.L1564Wfs*32 (Frameshift)		KIRC_CONSENSUS2	TCGA-CJ-5679-01A-11D-1534-10	TCGA-CJ-5679-11A-01D-1535-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.Q1560Nfs*37	0.4222	45.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Q1560Nfs*37 (Frameshift)		KIRC_CONSENSUS2	TCGA-CZ-5460-01A-01D-1501-10	TCGA-CZ-5460-11A-01D-1501-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.P1534Hfs*5	0.4242	33.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.P1534Hfs*5 (Frameshift)		KIRC_CONSENSUS2	TCGA-CW-5580-01A-01D-1669-08	TCGA-CW-5580-11A-02D-1669-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.Q1511Sfs*28	0.4571	35.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Q1511Sfs*28 (Frameshift)		KIRC_CONSENSUS2	TCGA-CZ-5456-01A-01D-1501-10	TCGA-CZ-5456-11A-01D-1501-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.V1505Lfs*34	0.2973	74.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.V1505Lfs*34 (Frameshift)		KIRC_CONSENSUS2	TCGA-A3-3316-01A-01D-0966-08	TCGA-A3-3316-11A-01D-0966-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.P1491Rfs*48	0.5778	45.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.P1491Rfs*48 (Frameshift)		KIRC_CONSENSUS2	TCGA-B0-5094-01A-01D-1421-08	TCGA-B0-5094-11A-01D-1421-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.Y1428*	0.2121	561.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Y1428* (Nonsense)		KIRC_CONSENSUS2	TCGA-BP-5169-01A-01D-1429-08	TCGA-BP-5169-11A-01D-1429-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.T1415Qfs*66	0.2578	419.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.T1415Qfs*66 (Frameshift)		KIRC_CONSENSUS2	TCGA-BP-5189-01A-02D-1429-08	TCGA-BP-5189-11A-01D-1429-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.D1403Lfs*18	0.1951	287.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.D1403Lfs*18 (Frameshift)		KIRC_CONSENSUS2	TCGA-B0-5110-01A-01D-1421-08	TCGA-B0-5110-11A-01D-1421-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.L1349Wfs*35	0.3714	70.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.L1349Wfs*35 (Frameshift)		KIRC_CONSENSUS2	TCGA-BP-5201-01A-01D-1429-08	TCGA-BP-5201-11A-01D-1429-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.Q1346Rfs*38	0.1429	70.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Q1346Rfs*38 (Frameshift)		KIRC_CONSENSUS2	TCGA-BP-4964-01A-01D-1462-08	TCGA-BP-4964-11A-01D-1462-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.P1339Lfs*45	0.2326	86.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.P1339Lfs*45 (Frameshift)		KIRC_CONSENSUS2	TCGA-B0-5097-01A-01D-1421-08	TCGA-B0-5097-11A-01D-1421-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.V1336Sfs*48	0.4364	110.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.V1336Sfs*48 (Frameshift)		KIRC_CONSENSUS2	TCGA-A3-3326-01A-01D-0966-08	TCGA-A3-3326-11A-01D-0966-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.Q1298*	0.3632	212.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Q1298* (Nonsense)		KIRC_CONSENSUS2	TCGA-CJ-5676-01A-11D-1534-10	TCGA-CJ-5676-11A-01D-1534-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.K1293Nfs*20	0.1967	122.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.K1293Nfs*20 (Frameshift)		KIRC_CONSENSUS2	TCGA-A3-3346-01A-01D-0966-08	TCGA-A3-3346-11A-01D-0966-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.Y1261*	0.4646	99.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Y1261* (Nonsense)		KIRC_CONSENSUS2	TCGA-CZ-5982-01A-11D-1669-08	TCGA-CZ-5982-11A-01D-1669-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.V1235Cfs*34	0.2466	73.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.V1235Cfs*34 (Frameshift)		KIRC_CONSENSUS2	TCGA-CZ-5989-01A-11D-1669-08	TCGA-CZ-5989-11A-01D-1669-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.E1222Kfs*5	0.4444	90.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.E1222Kfs*5 (Frameshift)		KIRC_CONSENSUS2	TCGA-B0-5698-01A-11D-1669-08	TCGA-B0-5698-10A-01D-1669-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.E1222Kfs*5	0.5625	64.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.E1222Kfs*5 (Frameshift)		KIRC_CONSENSUS2	TCGA-A3-3322-01A-01D-0966-08	TCGA-A3-3322-11A-01D-0966-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.F1216Yfs*3	0.1957	46.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.F1216Yfs*3 (Frameshift)		KIRC_CONSENSUS2	TCGA-A3-A6NJ-01A-12D-A33K-10	TCGA-A3-A6NJ-10A-01D-A33K-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.E1214Rfs*6	0.3158	38.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.E1214Rfs*6 (Frameshift)		KIRC_CONSENSUS2	TCGA-CJ-4913-01A-01D-1429-08	TCGA-CJ-4913-11A-01D-1429-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.I1197Ffs*21	0.3779	434.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.I1197Ffs*21 (Frameshift)		KIRC_CONSENSUS2	TCGA-CZ-5470-01A-01D-1501-10	TCGA-CZ-5470-11A-01D-1501-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.R1185*	0.1755	433.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R1185* (Nonsense)		KIRC_CONSENSUS2	TCGA-CJ-5684-01A-11D-1534-10	TCGA-CJ-5684-11A-01D-1535-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.G1161Afs*57	0.2963	135.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.G1161Afs*57 (Frameshift)		KIRC_CONSENSUS2	TCGA-BP-5184-01A-01D-1429-08	TCGA-BP-5184-11A-01D-1429-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.E1132*	0.33	100.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.E1132* (Nonsense)		KIRC_CONSENSUS2	TCGA-B4-5836-01A-11D-1669-08	TCGA-B4-5836-10A-01D-1669-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.N1126Gfs*15	0.2252	302.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.N1126Gfs*15 (Frameshift)		KIRC_CONSENSUS2	TCGA-CJ-4916-01A-01D-1429-08	TCGA-CJ-4916-11A-01D-1429-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.A1104Gfs*3	0.3759	266.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.A1104Gfs*3 (Frameshift)		KIRC_CONSENSUS2	TCGA-CJ-5678-01A-11D-1534-10	TCGA-CJ-5678-11A-01D-1534-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.I1073Lfs*86	0.2651	83.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.I1073Lfs*86 (Frameshift)		KIRC_CONSENSUS2	TCGA-G6-A8L7-01A-11D-A36X-10	TCGA-G6-A8L7-10A-01D-A370-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.R1052*	0.0902	122.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R1052* (Nonsense)		KIRC_CONSENSUS2	TCGA-B0-4842-01A-02D-1421-08	TCGA-B0-4842-11A-01D-1421-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.S1020*	0.4667	90.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.S1020* (Frameshift)		KIRC_CONSENSUS2	TCGA-BP-4975-01A-01D-1462-08	TCGA-BP-4975-11A-01D-1462-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.E1016*	0.2	50.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.E1016* (Nonsense)		KIRC_CONSENSUS2	TCGA-CJ-4913-01A-01D-1429-08	TCGA-CJ-4913-11A-01D-1429-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.R1010*	0.2222	27.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R1010* (Nonsense)		KIRC_CONSENSUS2	TCGA-DV-A4W0-01A-11D-A25V-10	TCGA-DV-A4W0-10A-01D-A25V-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.L993Mfs*20	0.56	100.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.L993Mfs*20 (Frameshift)		KIRC_CONSENSUS2	TCGA-CJ-4912-01A-01D-1429-08	TCGA-CJ-4912-11A-01D-1429-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.W992Mfs*12	0.2571	70.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.W992Mfs*12 (Frameshift)		KIRC_CONSENSUS2	TCGA-CJ-4904-01A-02D-1429-08	TCGA-CJ-4904-11A-01D-1429-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.K991Nfs*23	0.3673	49.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.K991Nfs*23 (Frameshift)		KIRC_CONSENSUS2	TCGA-B0-5113-01A-01D-1421-08	TCGA-B0-5113-11A-01D-1421-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.E981*	0.3837	245.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.E981* (Nonsense)		KIRC_CONSENSUS2	TCGA-BP-4985-01A-01D-1462-08	TCGA-BP-4985-11A-01D-1462-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.I977Rfs*4	0.45	280.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.I977Rfs*4 (Frameshift)		KIRC_CONSENSUS2	TCGA-BP-5198-01A-01D-1429-08	TCGA-BP-5198-11A-01D-1429-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.K930Rfs*84	0.3689	206.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.K930Rfs*84 (Frameshift)		KIRC_CONSENSUS2	TCGA-BP-5168-01A-01D-1421-08	TCGA-BP-5168-11A-01D-1421-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.R921*	0.2447	331.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R921* (Nonsense)		KIRC_CONSENSUS2	TCGA-CZ-5455-01A-01D-1501-10	TCGA-CZ-5455-11A-01D-1501-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.K909Nfs*6	0.3077	26.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.K909Nfs*6 (Frameshift)		KIRC_CONSENSUS2	TCGA-A3-A6NN-01A-12D-A33K-10	TCGA-A3-A6NN-10A-01D-A33K-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.Q869*	0.4828	58.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Q869* (Nonsense)		KIRC_CONSENSUS2	TCGA-BP-5180-01A-01D-1429-08	TCGA-BP-5180-11A-01D-1429-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.Q869Sfs*6	0.25	40.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Q869Sfs*6 (Frameshift)		KIRC_CONSENSUS2	TCGA-B4-5832-01A-11D-1669-08	TCGA-B4-5832-10A-01D-1669-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.R850*	0.1443	97.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R850* (Nonsense)		KIRC_CONSENSUS2	TCGA-BP-4988-01A-01D-1462-08	TCGA-BP-4988-11A-01D-1462-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.R850*	0.093	86.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R850* (Nonsense)		KIRC_CONSENSUS2	TCGA-BP-4993-01A-02D-1421-08	TCGA-BP-4993-11A-01D-1421-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.E846*	0.3846	117.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.E846* (Nonsense)		KIRC_CONSENSUS2	TCGA-CJ-4903-01A-01D-1429-08	TCGA-CJ-4903-11A-01D-1429-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.R836Lfs*12	0.225	80.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R836Lfs*12 (Frameshift)		KIRC_CONSENSUS2	TCGA-B0-5116-01A-02D-1421-08	TCGA-B0-5116-11A-01D-1421-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.N832Ifs*23	0.352	250.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.N832Ifs*23 (Frameshift)		KIRC_CONSENSUS2	TCGA-B0-5696-01A-11D-1534-10	TCGA-B0-5696-11A-01D-1534-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.S788*	0.2094	191.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.S788* (Nonsense)		KIRC_CONSENSUS2	TCGA-CZ-5466-01A-01D-1501-10	TCGA-CZ-5466-11A-01D-1501-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.Q779*	0.3656	93.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Q779* (Nonsense)		KIRC_CONSENSUS2	TCGA-A3-3387-01A-01D-1534-10	TCGA-A3-3387-11A-01D-1534-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.D748Mfs*27	0.3861	101.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.D748Mfs*27 (Frameshift)		KIRC_CONSENSUS2	TCGA-A3-A8OU-01A-11D-A36X-10	TCGA-A3-A8OU-10A-01D-A370-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.D748Mfs*27	0.3529	119.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.D748Mfs*27 (Frameshift)		KIRC_CONSENSUS2	TCGA-B0-5710-01A-11D-1669-08	TCGA-B0-5710-11A-01D-1669-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.Q719*	0.6154	156.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Q719* (Nonsense)		KIRC_CONSENSUS2	TCGA-G6-A8L8-01A-21D-A36X-10	TCGA-G6-A8L8-10A-01D-A370-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.R710*	0.4211	133.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R710* (Nonsense)		KIRC_CONSENSUS2	TCGA-B0-5700-01A-11D-1534-10	TCGA-B0-5700-11A-01D-1534-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.R710*	0.2723	213.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R710* (Nonsense)		KIRC_CONSENSUS2	TCGA-BP-5187-01A-01D-1429-08	TCGA-BP-5187-11A-01D-1429-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.Y697*	0.375	144.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Y697* (Frameshift)		KIRC_CONSENSUS2	TCGA-B2-5639-01A-01D-1534-10	TCGA-B2-5639-10A-01D-1535-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.R690*	0.4765	170.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R690* (Nonsense)		KIRC_CONSENSUS2	TCGA-B0-5085-01A-01D-1462-08	TCGA-B0-5085-11A-01D-1462-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.Y666*	0.3671	158.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Y666* (Nonsense)		KIRC_CONSENSUS2	TCGA-B0-5711-01A-11D-1669-08	TCGA-B0-5711-11A-01D-1669-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.N663Mfs*7	0.4746	118.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.N663Mfs*7 (Frameshift)		KIRC_CONSENSUS2	TCGA-CZ-5451-01A-01D-1501-10	TCGA-CZ-5451-11A-01D-1501-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.K640*	0.2344	64.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.K640* (Nonsense)		KIRC_CONSENSUS2	TCGA-A3-3320-01A-01D-0966-08	TCGA-A3-3320-11A-01D-0966-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.K638Nfs*4	0.3565	115.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.K638Nfs*4 (Frameshift)		KIRC_CONSENSUS2	TCGA-BP-4960-01A-01D-1462-08	TCGA-BP-4960-11A-01D-1462-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.L617Ffs*25	0.4706	170.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.L617Ffs*25 (Frameshift)		KIRC_CONSENSUS2	TCGA-B0-5693-01A-11D-1534-10	TCGA-B0-5693-11A-01D-1534-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.Y600Ifs*42	0.4127	63.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Y600Ifs*42 (Frameshift)		KIRC_CONSENSUS2	TCGA-BP-5190-01A-01D-1429-08	TCGA-BP-5190-11A-01D-1429-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.G582Rfs*18	0.3168	101.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.G582Rfs*18 (Frameshift)		KIRC_CONSENSUS2	TCGA-CJ-4920-01A-01D-1429-08	TCGA-CJ-4920-11A-01D-1429-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.E572*	0.3788	132.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.E572* (Frameshift)		KIRC_CONSENSUS2	TCGA-BP-5183-01A-01D-1429-08	TCGA-BP-5183-11A-01D-1429-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.I571Mfs*16	0.4173	278.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.I571Mfs*16 (Frameshift)		KIRC_CONSENSUS2	TCGA-B0-5705-01A-11D-1534-10	TCGA-B0-5705-11A-01D-1534-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.Y559*	0.3404	94.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Y559* (Nonsense)		KIRC_CONSENSUS2	TCGA-A3-3372-01A-01W-0886-08	TCGA-A3-3372-11A-01D-0966-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.N517Hfs*15	0.5833	48.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.N517Hfs*15 (Frameshift)		KIRC_CONSENSUS2	TCGA-B0-5712-01A-11D-1669-08	TCGA-B0-5712-11A-01D-1669-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.S502*	0.8507	67.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.S502* (Nonsense)		KIRC_CONSENSUS2	TCGA-EU-5907-01A-11D-1669-08	TCGA-EU-5907-10A-01D-1669-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.K485*	0.2891	128.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.K485* (Nonsense)		KIRC_CONSENSUS2	TCGA-CJ-4908-01A-01D-1429-08	TCGA-CJ-4908-11A-01D-1429-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.Q481Rfs*19	0.4545	88.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Q481Rfs*19 (Frameshift)		KIRC_CONSENSUS2	TCGA-BP-4981-01A-01D-1462-08	TCGA-BP-4981-11A-01D-1462-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.Q481*	0.6374	91.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Q481* (Nonsense)		KIRC_CONSENSUS2	TCGA-A3-3382-01A-01D-0966-08	TCGA-A3-3382-11A-01D-0966-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.E457*	0.4149	94.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.E457* (Nonsense)		KIRC_CONSENSUS2	TCGA-B0-5115-01A-01D-1421-08	TCGA-B0-5115-11A-01D-1421-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.Q440*	0.3043	23.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Q440* (Nonsense)		KIRC_CONSENSUS2	TCGA-BP-4999-01A-01D-1462-08	TCGA-BP-4999-11A-01D-1462-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.Q422*	0.232	250.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Q422* (Nonsense)		KIRC_CONSENSUS2	TCGA-BP-5170-01A-01D-1429-08	TCGA-BP-5170-11A-01D-1429-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.Y417Ifs*3	0.379	219.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Y417Ifs*3 (Frameshift)		KIRC_CONSENSUS2	TCGA-B0-5121-01A-02D-1421-08	TCGA-B0-5121-11A-01D-1421-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.Y409Tfs*29	0.4528	106.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Y409Tfs*29 (Frameshift)		KIRC_CONSENSUS2	TCGA-G6-A8L6-01A-11D-A36X-10	TCGA-G6-A8L6-10A-01D-A370-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.E368*	0.3269	104.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.E368* (Nonsense)		KIRC_CONSENSUS2	TCGA-B0-5399-01A-01D-1501-10	TCGA-B0-5399-10A-01D-1501-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.R332Vfs*30	0.6043	278.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R332Vfs*30 (Frameshift)		KIRC_CONSENSUS2	TCGA-CZ-5453-01A-01D-1501-10	TCGA-CZ-5453-11A-01D-1501-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.N325Ifs*37	0.209	134.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.N325Ifs*37 (Frameshift)		KIRC_CONSENSUS2	TCGA-A3-3378-01A-01D-0966-08	TCGA-A3-3378-11A-01D-0966-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.E291Dfs*3	0.32	50.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.E291Dfs*3 (Frameshift)		KIRC_CONSENSUS2	TCGA-A3-A8OW-01A-11D-A36X-10	TCGA-A3-A8OW-10A-01D-A370-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.K283Rfs*3	0.1471	34.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.K283Rfs*3 (Frameshift)		KIRC_CONSENSUS2	TCGA-BP-5176-01A-01D-1429-08	TCGA-BP-5176-11A-01D-1429-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.I279Nfs*8	0.3333	18.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.I279Nfs*8 (Frameshift)		KIRC_CONSENSUS2	TCGA-B0-5713-01A-11D-1669-08	TCGA-B0-5713-11A-01D-1669-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.K243*	0.3678	174.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.K243* (Nonsense)		KIRC_CONSENSUS2	TCGA-A3-3373-01A-02D-1421-08	TCGA-A3-3373-11A-01D-1421-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.Q209*	0.52	150.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Q209* (Nonsense)		KIRC_CONSENSUS2	TCGA-B0-5694-01A-11D-1534-10	TCGA-B0-5694-11A-01D-1534-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.Q209Rfs*15	0.493	71.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Q209Rfs*15 (Frameshift)		KIRC_CONSENSUS2	TCGA-CZ-5986-01A-11D-1669-08	TCGA-CZ-5986-11A-01D-1669-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.V194Cfs*11	0.22	100.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.V194Cfs*11 (Frameshift)		KIRC_CONSENSUS2	TCGA-B2-4101-01A-02D-1458-08	TCGA-B2-4101-11A-01D-1458-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.Q188*	0.3886	211.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Q188* (Nonsense)		KIRC_CONSENSUS2	TCGA-DV-5566-01A-01D-1534-10	TCGA-DV-5566-10A-01D-1535-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.T172Qfs*2	0.265	400.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.T172Qfs*2 (Frameshift)		KIRC_CONSENSUS2	TCGA-A3-3365-01A-01D-0966-08	TCGA-A3-3365-11A-01D-0966-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.Q170*	0.3144	404.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Q170* (Nonsense)		KIRC_CONSENSUS2	TCGA-BP-5195-01A-02D-1429-08	TCGA-BP-5195-11A-01D-1429-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.E160Kfs*14	0.658	193.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.E160Kfs*14 (Frameshift)		KIRC_CONSENSUS2	TCGA-CZ-5465-01A-01D-1806-10	TCGA-CZ-5465-11A-01D-1501-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.E160*	0.6	300.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.E160* (Nonsense)		KIRC_CONSENSUS2	TCGA-CZ-5454-01A-01D-1501-10	TCGA-CZ-5454-11A-01D-1501-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.D142Gfs*9	0.3051	118.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.D142Gfs*9 (Frameshift)		KIRC_CONSENSUS2	TCGA-CJ-6030-01A-11D-1669-08	TCGA-CJ-6030-11A-01D-1669-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.Y134Ifs*2	0.3302	106.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Y134Ifs*2 (Frameshift)		KIRC_CONSENSUS2	TCGA-B0-5120-01A-01D-1421-08	TCGA-B0-5120-11A-01D-1421-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.N122Kfs*47	0.168	369.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.N122Kfs*47 (Frameshift)		KIRC_CONSENSUS2	TCGA-CJ-5671-01A-11D-1534-10	TCGA-CJ-5671-11A-01D-1534-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.F120*	0.1935	62.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.F120* (Frameshift)		KIRC_CONSENSUS2	TCGA-CJ-4900-01A-01D-1462-08	TCGA-CJ-4900-11A-01D-1462-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.D115Sfs*57	0.2667	60.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.D115Sfs*57 (Frameshift)		KIRC_CONSENSUS2	TCGA-BP-5194-01A-02D-1429-08	TCGA-BP-5194-11A-01D-1429-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.N110Ifs*3	0.4694	49.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.N110Ifs*3 (Frameshift)		KIRC_CONSENSUS2	TCGA-A3-3383-01A-01D-0966-08	TCGA-A3-3383-11A-01D-0966-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.K96*	0.3671	79.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.K96* (Nonsense)		KIRC_CONSENSUS2	TCGA-BP-4982-01A-01D-1462-08	TCGA-BP-4982-11A-01D-1462-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.D59Mfs*33	0.1579	76.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.D59Mfs*33 (Frameshift)		KIRC_CONSENSUS2	TCGA-B0-5812-01A-11D-1669-08	TCGA-B0-5812-11A-01D-1669-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.R58*	0.4234	111.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R58* (Nonsense)		KIRC_CONSENSUS2	TCGA-BP-4987-01A-01D-1462-08	TCGA-BP-4987-11A-01D-1462-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.C50Afs*45	0.6667	48.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.C50Afs*45 (Frameshift)		KIRC_CONSENSUS2	TCGA-B8-4151-01A-01D-1806-10	TCGA-B8-4151-10A-01D-1251-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.V44Cfs*9	0.561	41.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.V44Cfs*9 (Frameshift)		KIRC_CONSENSUS2	TCGA-CZ-5987-01A-11D-1669-08	TCGA-CZ-5987-11A-01D-1669-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.S39Ffs*4	0.32	100.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.S39Ffs*4 (Frameshift)		KIRC_CONSENSUS2	TCGA-CJ-4905-01A-02D-1429-08	TCGA-CJ-4905-11A-01D-1429-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC1	Frameshift	p.G443Dfs*14	0.187	123.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC1 p.G443Dfs*14 (Frameshift)		KIRC_CONSENSUS2	TCGA-B0-4842-01A-02D-1421-08	TCGA-B0-4842-11A-01D-1421-08
Investigate Actionability	Clinical evidence			Somatic Variant	ARAF	Missense	p.R30S	0.2353	17.0	0.0	0.0		Investigate Actionability	Sorafenib	RAF inhibition	Targeted therapy	Activating mutations in ARAF may predict sensitivity to sorafenib or other RAF inhibitors. Patient received 5 year response to sorafenib with ARAF S214C.	Imielinski M, Greulich H, Kaplan B, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014;124(4):1582-6.	https://doi.org/10.1172/JCI72763																	ARAF p.R30S (Missense)	0	KIRC_CONSENSUS2	TCGA-A3-3319-01A-01D-0966-08	TCGA-A3-3319-11A-01D-0966-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Frameshift	p.I122Wfs*53	0.6354	96.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.I122Wfs*53 (Frameshift)	1	KIRC_CONSENSUS2	TCGA-EU-5907-01A-11D-1669-08	TCGA-EU-5907-10A-01D-1669-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Frameshift	p.R130Lfs*3	0.2576	264.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.R130Lfs*3 (Frameshift)	1	KIRC_CONSENSUS2	TCGA-B0-5706-01A-11D-1534-10	TCGA-B0-5706-11A-01D-1534-10
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Frameshift	p.C136Mfs*44	0.191	199.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.C136Mfs*44 (Frameshift)	1	KIRC_CONSENSUS2	TCGA-A3-3346-01A-01D-0966-08	TCGA-A3-3346-11A-01D-0966-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Frameshift	p.L146*	0.2147	191.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.L146* (Frameshift)	1	KIRC_CONSENSUS2	TCGA-A3-3308-01A-01D-0966-08	TCGA-A3-3308-11A-01D-0966-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Nonsense	p.Y176*	0.3404	564.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.Y176* (Nonsense)	1	KIRC_CONSENSUS2	TCGA-DV-5568-01A-01D-1534-10	TCGA-DV-5568-10A-01D-1535-10
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Frameshift	p.K197Qfs*5	0.2241	232.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.K197Qfs*5 (Frameshift)	1	KIRC_CONSENSUS2	TCGA-BP-5010-01A-02D-1421-08	TCGA-BP-5010-11A-01D-1421-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Splice Site	p.X212_splice	0.2047	386.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.X212_splice (Splice Site)	1	KIRC_CONSENSUS2	TCGA-A3-3308-01A-01D-0966-08	TCGA-A3-3308-11A-01D-0966-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Nonsense	p.K263*	0.1471	102.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.K263* (Nonsense)	1	KIRC_CONSENSUS2	TCGA-B8-5158-01A-01D-1421-08	TCGA-B8-5158-10A-01D-1421-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.E769G	0.0788	203.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.E769G (Missense)	1	KIRC_CONSENSUS2	TCGA-CJ-4905-01A-02D-1429-08	TCGA-CJ-4905-11A-01D-1429-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.K1352N	0.2116	189.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.K1352N (Missense)		KIRC_CONSENSUS2	TCGA-B8-5163-01A-01D-1421-08	TCGA-B8-5163-10A-01D-1421-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.S865P	0.3799	179.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.S865P (Missense)		KIRC_CONSENSUS2	TCGA-CJ-5682-01A-11D-1534-10	TCGA-CJ-5682-11A-01D-1535-10
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.D282E	0.2326	86.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.D282E (Missense)		KIRC_CONSENSUS2	TCGA-B0-5694-01A-11D-1534-10	TCGA-B0-5694-11A-01D-1534-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.P400Hfs*33	0.28	50.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P400Hfs*33 (Frameshift)		KIRC_CONSENSUS2	TCGA-B0-5705-01A-11D-1534-10	TCGA-B0-5705-11A-01D-1534-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.P554Hfs*65	0.3537	164.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P554Hfs*65 (Frameshift)		KIRC_CONSENSUS2	TCGA-B0-5692-01A-11D-1534-10	TCGA-B0-5692-11A-01D-1534-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.G665Dfs*10	0.5865	133.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.G665Dfs*10 (Frameshift)		KIRC_CONSENSUS2	TCGA-B0-5102-01A-01D-1421-08	TCGA-B0-5102-11A-01D-1421-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.P947Hfs*21	0.3133	83.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P947Hfs*21 (Frameshift)		KIRC_CONSENSUS2	TCGA-GK-A6C7-01A-11D-A33K-10	TCGA-GK-A6C7-10B-01D-A33K-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.E1006*	0.2472	89.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.E1006* (Nonsense)		KIRC_CONSENSUS2	TCGA-CJ-6032-01A-11D-1669-08	TCGA-CJ-6032-11A-01D-1669-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q1098*	0.102	98.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q1098* (Nonsense)		KIRC_CONSENSUS2	TCGA-AK-3444-01A-01D-0966-08	TCGA-AK-3444-10A-01D-0966-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.G1139Lfs*21	0.2045	88.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.G1139Lfs*21 (Frameshift)		KIRC_CONSENSUS2	TCGA-B0-4945-01A-01D-1421-08	TCGA-B0-4945-11A-01D-1421-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.F1728Wfs*7	0.2587	286.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.F1728Wfs*7 (Frameshift)		KIRC_CONSENSUS2	TCGA-B0-5713-01A-11D-1669-08	TCGA-B0-5713-11A-01D-1669-08
Investigate Actionability	Preclinical			Somatic Variant	AKT3	Missense	p.E17K	0.2121	66.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT3 p.E17K (Missense)	0	KIRC_CONSENSUS2	TCGA-BP-5009-01A-01D-1462-08	TCGA-BP-5009-11A-01D-1462-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.A749T	0.3299	385.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.A749T (Missense)	1	KIRC_CONSENSUS2	TCGA-B0-5703-01A-11D-1534-10	TCGA-B0-5703-11A-01D-1534-10
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.T909I	0.2192	73.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.T909I (Missense)	1	KIRC_CONSENSUS2	TCGA-A3-A6NN-01A-12D-A33K-10	TCGA-A3-A6NN-10A-01D-A33K-10
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.A1123T	0.1194	67.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.A1123T (Missense)	1	KIRC_CONSENSUS2	TCGA-B4-5832-01A-11D-1669-08	TCGA-B4-5832-10A-01D-1669-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.V1678G	0.2527	273.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.V1678G (Missense)	1	KIRC_CONSENSUS2	TCGA-CJ-4904-01A-02D-1429-08	TCGA-CJ-4904-11A-01D-1429-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.T2264I	0.2135	89.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.T2264I (Missense)	1	KIRC_CONSENSUS2	TCGA-B8-4622-01A-02D-1553-08	TCGA-B8-4622-11A-01D-1553-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.N2494Y	0.3166	477.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.N2494Y (Missense)	1	KIRC_CONSENSUS2	TCGA-CZ-5451-01A-01D-1501-10	TCGA-CZ-5451-11A-01D-1501-10
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.G2718R	0.5	20.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.G2718R (Missense)	1	KIRC_CONSENSUS2	TCGA-BP-5173-01A-01D-1429-08	TCGA-BP-5173-11A-01D-1429-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.L2965S	0.2041	98.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.L2965S (Missense)	1	KIRC_CONSENSUS2	TCGA-CJ-4900-01A-01D-1462-08	TCGA-CJ-4900-11A-01D-1462-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.K3004E	0.1301	146.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.K3004E (Missense)	1	KIRC_CONSENSUS2	TCGA-BP-4964-01A-01D-1462-08	TCGA-BP-4964-11A-01D-1462-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Splice Site	p.X813_splice	0.2987	154.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.X813_splice (Splice Site)		KIRC_CONSENSUS2	TCGA-BP-4963-01A-01D-1462-08	TCGA-BP-4963-11A-01D-1462-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Splice Site	p.X1183_splice	0.4912	57.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.X1183_splice (Splice Site)		KIRC_CONSENSUS2	TCGA-B0-5098-01A-01D-1421-08	TCGA-B0-5098-11A-01D-1421-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.P747H	0.1124	178.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.P747H (Missense)	0	KIRC_CONSENSUS2	TCGA-BP-5182-01A-01D-1429-08	TCGA-BP-5182-11A-01D-1429-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.Q326E	0.2727	77.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.Q326E (Missense)	0	KIRC_CONSENSUS2	TCGA-B0-5694-01A-11D-1534-10	TCGA-B0-5694-11A-01D-1534-10
Investigate Actionability	Preclinical			Somatic Variant	AKT2	Missense	p.D324H	0.2444	90.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT2 p.D324H (Missense)	0	KIRC_CONSENSUS2	TCGA-B2-4101-01A-02D-1458-08	TCGA-B2-4101-11A-01D-1458-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.V143D	0.3243	111.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.V143D (Missense)		KIRC_CONSENSUS2	TCGA-B0-5102-01A-01D-1421-08	TCGA-B0-5102-11A-01D-1421-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.V504L	0.43	200.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.V504L (Missense)	0	KIRC_CONSENSUS2	TCGA-EU-5907-01A-11D-1669-08	TCGA-EU-5907-10A-01D-1669-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.V1070E	0.2832	226.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.V1070E (Missense)	0	KIRC_CONSENSUS2	TCGA-CW-6087-01A-11D-1669-08	TCGA-CW-6087-11A-01D-1669-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.L1205V	0.4324	222.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.L1205V (Missense)	0	KIRC_CONSENSUS2	TCGA-B0-5707-01A-11D-1534-10	TCGA-B0-5707-11A-01D-1534-10
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.I1487M	0.2727	154.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.I1487M (Missense)		KIRC_CONSENSUS2	TCGA-AS-3778-01A-01D-0966-08	TCGA-AS-3778-10A-01D-0966-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.Q1475H	0.1969	127.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.Q1475H (Missense)		KIRC_CONSENSUS2	TCGA-A3-3370-01A-02D-1421-08	TCGA-A3-3370-11A-01D-1421-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.L1137M	0.21	100.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.L1137M (Missense)		KIRC_CONSENSUS2	TCGA-CJ-4918-01A-01D-1429-08	TCGA-CJ-4918-11A-01D-1429-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.N882S	0.12	100.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.N882S (Missense)		KIRC_CONSENSUS2	TCGA-A3-A8OX-01A-11D-A36X-10	TCGA-A3-A8OX-10A-01D-A370-10
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.S879Y	0.3889	36.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.S879Y (Missense)		KIRC_CONSENSUS2	TCGA-CJ-4913-01A-01D-1429-08	TCGA-CJ-4913-11A-01D-1429-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.D281Y	0.1818	121.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.D281Y (Missense)		KIRC_CONSENSUS2	TCGA-CJ-5677-01A-11D-1534-10	TCGA-CJ-5677-11A-01D-1534-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.V272M	0.4215	121.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V272M (Missense)		KIRC_CONSENSUS2	TCGA-CZ-5463-01A-01D-1501-10	TCGA-CZ-5463-11A-01D-1501-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X261_splice	0.7119	118.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X261_splice (Splice Site)		KIRC_CONSENSUS2	TCGA-BP-4770-01A-01D-1501-10	TCGA-BP-4770-11A-01D-1501-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.S241C	0.0949	137.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.S241C (Missense)		KIRC_CONSENSUS2	TCGA-CZ-4865-01A-02D-1501-10	TCGA-CZ-4865-11A-01D-1501-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R213*	0.266	94.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R213* (Nonsense)		KIRC_CONSENSUS2	TCGA-B0-5098-01A-01D-1421-08	TCGA-B0-5098-11A-01D-1421-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.H193Y	0.5333	75.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H193Y (Missense)		KIRC_CONSENSUS2	TCGA-B0-5117-01A-01D-1421-08	TCGA-B0-5117-11A-01D-1421-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.H178Qfs*3	0.1589	107.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H178Qfs*3 (Frameshift)		KIRC_CONSENSUS2	TCGA-A3-3346-01A-01D-0966-08	TCGA-A3-3346-11A-01D-0966-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X32_splice	0.8909	55.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X32_splice (Splice Site)		KIRC_CONSENSUS2	TCGA-AK-3440-01A-01D-0966-08	TCGA-AK-3440-10A-01D-0966-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.S75R	0.3741	139.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.S75R (Missense)		KIRC_CONSENSUS2	TCGA-B0-5696-01A-11D-1534-10	TCGA-B0-5696-11A-01D-1534-10
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.A365V	0.2396	192.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.A365V (Missense)		KIRC_CONSENSUS2	TCGA-CJ-4920-01A-01D-1429-08	TCGA-CJ-4920-11A-01D-1429-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.S244L	0.2857	77.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.S244L (Missense)		KIRC_CONSENSUS2	TCGA-B8-5159-01A-01D-1421-08	TCGA-B8-5159-10A-01D-1421-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.S23C	0.3333	12.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.S23C (Missense)		KIRC_CONSENSUS2	TCGA-CZ-4853-01A-01D-1429-08	TCGA-CZ-4853-11A-01D-1429-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.S397L	0.2143	56.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.S397L (Missense)		KIRC_CONSENSUS2	TCGA-A3-3358-01A-01D-1534-10	TCGA-A3-3358-11A-01D-1534-10
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.L853M	0.2466	73.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.L853M (Missense)		KIRC_CONSENSUS2	TCGA-BP-4982-01A-01D-1462-08	TCGA-BP-4982-11A-01D-1462-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.A1382T	0.2088	91.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.A1382T (Missense)		KIRC_CONSENSUS2	TCGA-CZ-4856-01A-02D-1429-08	TCGA-CZ-4856-11A-01D-1429-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Frameshift	p.S839Pfs*2	0.3333	240.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.S839Pfs*2 (Frameshift)		KIRC_CONSENSUS2	TCGA-B0-5697-01A-11D-1534-10	TCGA-B0-5697-11A-01D-1534-10
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.R720P	0.2051	156.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.R720P (Missense)		KIRC_CONSENSUS2	TCGA-B4-5836-01A-11D-1669-08	TCGA-B4-5836-10A-01D-1669-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Frameshift	p.E616Dfs*35	0.1556	45.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.E616Dfs*35 (Frameshift)		KIRC_CONSENSUS2	TCGA-BP-4999-01A-01D-1462-08	TCGA-BP-4999-11A-01D-1462-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.M585L	0.2564	39.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.M585L (Missense)		KIRC_CONSENSUS2	TCGA-B0-5120-01A-01D-1421-08	TCGA-B0-5120-11A-01D-1421-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.F290I	0.42	100.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.F290I (Missense)		KIRC_CONSENSUS2	TCGA-BP-5181-01A-01D-1429-08	TCGA-BP-5181-11A-01D-1429-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.S1207L	0.1783	387.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.S1207L (Missense)		KIRC_CONSENSUS2	TCGA-CJ-5672-01A-11D-1534-10	TCGA-CJ-5672-11A-01D-1534-10
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.K741E	0.3647	170.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.K741E (Missense)		KIRC_CONSENSUS2	TCGA-DV-A4W0-01A-11D-A25V-10	TCGA-DV-A4W0-10A-01D-A25V-10
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Nonsense	p.E997*	0.25	96.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.E997* (Nonsense)		KIRC_CONSENSUS2	TCGA-BP-4983-01A-01D-1462-08	TCGA-BP-4983-11A-01D-1462-08
Investigate Actionability			Guideline	Somatic Variant	BCOR	Nonsense	p.Y972*	0.3333	66.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					BCOR p.Y972* (Nonsense)		KIRC_CONSENSUS2	TCGA-B8-5550-01A-01D-1534-10	TCGA-B8-5550-10A-01D-1535-10
Investigate Actionability			Guideline	Somatic Variant	STAG2	Frameshift	p.D515*	0.3529	68.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.D515* (Frameshift)		KIRC_CONSENSUS2	TCGA-CZ-5466-01A-01D-1501-10	TCGA-CZ-5466-11A-01D-1501-10
Investigate Actionability			Guideline	Somatic Variant	STAG2	Frameshift		0.52	100.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2  (Frameshift)		KIRC_CONSENSUS2	TCGA-MM-A564-01A-11D-A25V-10	TCGA-MM-A564-10A-01D-A25V-10
Investigate Actionability			Guideline	Somatic Variant	STAG2	Nonsense	p.R604*	0.6667	66.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.R604* (Nonsense)		KIRC_CONSENSUS2	TCGA-BP-4985-01A-01D-1462-08	TCGA-BP-4985-11A-01D-1462-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Nonsense	p.Y636*	0.5823	79.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.Y636* (Nonsense)		KIRC_CONSENSUS2	TCGA-BP-5191-01A-01D-1429-08	TCGA-BP-5191-11A-01D-1429-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Frameshift	p.E750Dfs*31	0.2444	90.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.E750Dfs*31 (Frameshift)		KIRC_CONSENSUS2	TCGA-B0-5712-01A-11D-1669-08	TCGA-B0-5712-11A-01D-1669-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Frameshift	p.L995*	0.5417	96.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.L995* (Frameshift)		KIRC_CONSENSUS2	TCGA-A3-3317-01A-01D-0966-08	TCGA-A3-3317-11A-01D-0966-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.D53A	0.1781	320.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.D53A (Missense)		KIRC_CONSENSUS2	TCGA-CJ-4918-01A-01D-1429-08	TCGA-CJ-4918-11A-01D-1429-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.S599I	0.3313	166.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.S599I (Missense)		KIRC_CONSENSUS2	TCGA-BP-4976-01A-01D-1462-08	TCGA-BP-4976-11A-01D-1462-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.D125G	0.186	86.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.D125G (Missense)	0	KIRC_CONSENSUS2	TCGA-B0-5077-01A-01D-1462-08	TCGA-B0-5077-11A-01D-1462-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.D189H	0.2045	528.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.D189H (Missense)	0	KIRC_CONSENSUS2	TCGA-B2-5641-01A-01D-1534-10	TCGA-B2-5641-10A-01D-1535-10
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.S313Y	0.1977	172.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.S313Y (Missense)	0	KIRC_CONSENSUS2	TCGA-BP-4801-01A-02D-1421-08	TCGA-BP-4801-11A-01D-1421-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.E832K	0.2263	137.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.E832K (Missense)	0	KIRC_CONSENSUS2	TCGA-A3-3365-01A-01D-0966-08	TCGA-A3-3365-11A-01D-0966-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.I2177V	0.202	99.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.I2177V (Missense)	0	KIRC_CONSENSUS2	TCGA-A3-3311-01A-01D-0966-08	TCGA-A3-3311-11A-01D-0966-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.P2800R	0.0962	291.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.P2800R (Missense)	0	KIRC_CONSENSUS2	TCGA-A3-3308-01A-01D-0966-08	TCGA-A3-3308-11A-01D-0966-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.F2841I	0.4	105.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.F2841I (Missense)	0	KIRC_CONSENSUS2	TCGA-CZ-5982-01A-11D-1669-08	TCGA-CZ-5982-11A-01D-1669-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.S2887T	0.3438	64.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.S2887T (Missense)	0	KIRC_CONSENSUS2	TCGA-A3-A8CQ-01A-11D-A36X-10	TCGA-A3-A8CQ-10A-01D-A370-10
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.A3297T	0.2941	187.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.A3297T (Missense)	0	KIRC_CONSENSUS2	TCGA-B8-4622-01A-02D-1553-08	TCGA-B8-4622-11A-01D-1553-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.P1831L	0.1505	93.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.P1831L (Missense)	1	KIRC_CONSENSUS2	TCGA-BP-4998-01A-01D-1462-08	TCGA-BP-4998-11A-01D-1462-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.N1309I	0.3675	332.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.N1309I (Missense)	1	KIRC_CONSENSUS2	TCGA-CZ-4853-01A-01D-1429-08	TCGA-CZ-4853-11A-01D-1429-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.N1309H	0.3598	328.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.N1309H (Missense)	1	KIRC_CONSENSUS2	TCGA-CZ-4853-01A-01D-1429-08	TCGA-CZ-4853-11A-01D-1429-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Nonsense	p.Y285*	0.2951	122.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.Y285* (Nonsense)		KIRC_CONSENSUS2	TCGA-A3-3380-01A-01D-0966-08	TCGA-A3-3380-11A-01D-0966-08
Investigate Actionability	FDA-Approved		Clinical trial	Somatic Variant	PIK3CA	Nonsense	p.Y272*	0.3836	73.0	0.0	0.0		Investigate Actionability	Alpelisib	PI3K/AKT/mTOR inhibition	Targeted therapy	Alpelisib is a kinase inhibitor indictated in combination with fulvestrant for the treatment of postmenopausal women, and men, with HR+, HER2-negative, PIK3CA mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endrocrine-based regime. 	Novartis Pharmaceuticals Corporation. Piqray (alpelisib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212526s001lbl.pdf. Revised September 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212526s001lbl.pdf								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.Y272* (Nonsense)	1	KIRC_CONSENSUS2	TCGA-B8-5159-01A-01D-1421-08	TCGA-B8-5159-10A-01D-1421-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Nonsense	p.Y551*	0.2883	111.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.Y551* (Nonsense)	1	KIRC_CONSENSUS2	TCGA-MM-A563-01A-11D-A25V-10	TCGA-MM-A563-10A-01D-A25V-10
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.S190L	0.0981	377.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.S190L (Missense)	0	KIRC_CONSENSUS2	TCGA-DV-5574-01A-01D-1534-10	TCGA-DV-5574-10A-01D-1535-10
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.R762H	0.1383	188.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.R762H (Missense)	1	KIRC_CONSENSUS2	TCGA-CZ-5465-01A-01D-1806-10	TCGA-CZ-5465-11A-01D-1501-10
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.D674Y	0.1146	192.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.D674Y (Missense)	1	KIRC_CONSENSUS2	TCGA-CJ-4882-01A-02D-1429-08	TCGA-CJ-4882-11A-01D-1429-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.T238I	0.436	289.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.T238I (Missense)	1	KIRC_CONSENSUS2	TCGA-B8-4621-01A-01D-1501-10	TCGA-B8-4621-10A-01D-1501-10
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Missense	p.V523I	0.1913	183.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.V523I (Missense)	0	KIRC_CONSENSUS2	TCGA-CZ-5462-01A-01D-1501-10	TCGA-CZ-5462-11A-01D-1501-10
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Missense	p.M104I	0.1148	122.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.M104I (Missense)	0	KIRC_CONSENSUS2	TCGA-CJ-4904-01A-02D-1429-08	TCGA-CJ-4904-11A-01D-1429-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK2	Missense	p.V109G	0.2669	311.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK2 p.V109G (Missense)	0	KIRC_CONSENSUS2	TCGA-CZ-5457-01A-01D-1501-10	TCGA-CZ-5457-11A-01D-1501-10
Investigate Actionability	FDA-Approved			Somatic Variant	RAD54L	Missense	p.P15H	0.2743	113.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	RAD54L p.P15H (Missense)	0	KIRC_CONSENSUS2	TCGA-B0-5701-01A-11D-1534-10	TCGA-B0-5701-11A-01D-1534-10
Investigate Actionability	FDA-Approved			Somatic Variant	RAD54L	Frameshift	p.P155Lfs*7	0.3373	166.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	RAD54L p.P155Lfs*7 (Frameshift)	0	KIRC_CONSENSUS2	TCGA-B0-5099-01A-01D-1421-08	TCGA-B0-5099-11A-01D-1421-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.D386N	0.328	125.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.D386N (Missense)		KIRC_CONSENSUS2	TCGA-BP-5181-01A-01D-1429-08	TCGA-BP-5181-11A-01D-1429-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.V868E	0.25	64.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.V868E (Missense)		KIRC_CONSENSUS2	TCGA-T7-A92I-01A-11D-A36X-10	TCGA-T7-A92I-10A-01D-A370-10
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Splice Site	p.X1204_splice	0.2963	54.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.X1204_splice (Splice Site)		KIRC_CONSENSUS2	TCGA-T7-A92I-01A-11D-A36X-10	TCGA-T7-A92I-10A-01D-A370-10
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.V1291I	0.2865	192.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.V1291I (Missense)		KIRC_CONSENSUS2	TCGA-A3-3322-01A-01D-0966-08	TCGA-A3-3322-11A-01D-0966-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Splice Site	p.X349_splice	0.2903	93.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.X349_splice (Splice Site)	0	KIRC_CONSENSUS2	TCGA-B0-5098-01A-01D-1421-08	TCGA-B0-5098-11A-01D-1421-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.L649R	0.1429	140.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.L649R (Missense)	0	KIRC_CONSENSUS2	TCGA-CZ-5468-01A-01D-1501-10	TCGA-CZ-5468-11A-01D-1501-10
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.R773H	0.1842	38.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.R773H (Missense)	0	KIRC_CONSENSUS2	TCGA-A3-3322-01A-01D-0966-08	TCGA-A3-3322-11A-01D-0966-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Nonsense	p.Q1088*	0.2121	99.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.Q1088* (Nonsense)	0	KIRC_CONSENSUS2	TCGA-B0-5706-01A-11D-1534-10	TCGA-B0-5706-11A-01D-1534-10
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.D1100N	0.2759	58.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.D1100N (Missense)	0	KIRC_CONSENSUS2	TCGA-B0-5693-01A-11D-1534-10	TCGA-B0-5693-11A-01D-1534-10
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Frameshift	p.I1188Tfs*27	0.3529	68.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.I1188Tfs*27 (Frameshift)	0	KIRC_CONSENSUS2	TCGA-CZ-5454-01A-01D-1501-10	TCGA-CZ-5454-11A-01D-1501-10
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Insertion	p.S1427_N1428insK	0.2041	98.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.S1427_N1428insK (Insertion)	0	KIRC_CONSENSUS2	TCGA-B2-5633-01A-01D-A270-10	TCGA-B2-5633-10A-01D-A270-10
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Splice Site	p.X830_splice	0.1368	117.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC1 p.X830_splice (Splice Site)		KIRC_CONSENSUS2	TCGA-B8-4621-01A-01D-1501-10	TCGA-B8-4621-10A-01D-1501-10
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Splice Site	p.X666_splice	0.2791	43.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC1 p.X666_splice (Splice Site)		KIRC_CONSENSUS2	TCGA-G6-A8L7-01A-11D-A36X-10	TCGA-G6-A8L7-10A-01D-A370-10
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Missense	p.H206R	0.375	96.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC1 p.H206R (Missense)		KIRC_CONSENSUS2	TCGA-B8-4622-01A-02D-1553-08	TCGA-B8-4622-11A-01D-1553-08
Investigate Actionability	Guideline			Somatic Variant	ERBB2	Frameshift	p.N388Qfs*14	0.3023	43.0	0.0	0.0		Investigate Actionability	Ado-Trastuzumab Emtansine	ER signaling inhibition	Hormone therapy	Ado-trasuzumab emtansine is an available targeted agent with activity against ERBB2 variants in metastatic, NSCLC.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 5.2019). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf																	ERBB2 p.N388Qfs*14 (Frameshift)		KIRC_CONSENSUS2	TCGA-CZ-4859-01A-02D-1429-08	TCGA-CZ-4859-11A-01D-1429-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Nonsense	p.E1031*	0.2516	155.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.E1031* (Nonsense)	0	KIRC_CONSENSUS2	TCGA-B0-5121-01A-02D-1421-08	TCGA-B0-5121-11A-01D-1421-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Frameshift	p.N312Yfs*18	0.12	50.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.N312Yfs*18 (Frameshift)		KIRC_CONSENSUS2	TCGA-B8-A54H-01A-11D-A33K-10	TCGA-B8-A54H-10A-01D-A33K-10
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.V449E	0.4444	54.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.V449E (Missense)		KIRC_CONSENSUS2	TCGA-B8-4153-01B-11D-1669-08	TCGA-B8-4153-11A-01D-1669-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.L757V	0.3	100.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.L757V (Missense)		KIRC_CONSENSUS2	TCGA-B0-5115-01A-01D-1421-08	TCGA-B0-5115-11A-01D-1421-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Nonsense	p.R1267*	0.1603	131.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.R1267* (Nonsense)		KIRC_CONSENSUS2	TCGA-B8-5165-01A-01D-1421-08	TCGA-B8-5165-10A-01D-1421-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Frameshift	p.R989Sfs*8	0.2833	120.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.R989Sfs*8 (Frameshift)		KIRC_CONSENSUS2	TCGA-CZ-5465-01A-01D-1806-10	TCGA-CZ-5465-11A-01D-1501-10
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.K829T	0.24	200.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.K829T (Missense)		KIRC_CONSENSUS2	TCGA-B0-5102-01A-01D-1421-08	TCGA-B0-5102-11A-01D-1421-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.A821S	0.1242	153.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.A821S (Missense)		KIRC_CONSENSUS2	TCGA-CJ-6031-01A-11D-1669-08	TCGA-CJ-6031-11A-01D-1669-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.Q200H	0.1781	73.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.Q200H (Missense)		KIRC_CONSENSUS2	TCGA-EU-5904-01A-11D-1669-08	TCGA-EU-5904-10A-01D-1669-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Missense	p.C707R	0.4054	148.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.C707R (Missense)		KIRC_CONSENSUS2	TCGA-A3-3385-01A-02D-1421-08	TCGA-A3-3385-11A-01D-1421-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.L423I	0.3077	130.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.L423I (Missense)		KIRC_CONSENSUS2	TCGA-BP-4972-01A-01D-1462-08	TCGA-BP-4972-11A-01D-1462-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.A1206E	0.3256	129.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.A1206E (Missense)		KIRC_CONSENSUS2	TCGA-A3-3322-01A-01D-0966-08	TCGA-A3-3322-11A-01D-0966-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.R1670P	0.1509	265.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R1670P (Missense)		KIRC_CONSENSUS2	TCGA-CJ-4923-01A-01D-1429-08	TCGA-CJ-4923-11A-01D-1429-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Splice Site	p.X1537_splice	0.2791	86.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.X1537_splice (Splice Site)		KIRC_CONSENSUS2	TCGA-B0-5690-01A-11D-1534-10	TCGA-B0-5690-11A-01D-1534-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.W1417G	0.2729	469.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.W1417G (Missense)		KIRC_CONSENSUS2	TCGA-BP-5189-01A-02D-1429-08	TCGA-BP-5189-11A-01D-1429-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.E1287D	0.5712	562.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.E1287D (Missense)		KIRC_CONSENSUS2	TCGA-CJ-5682-01A-11D-1534-10	TCGA-CJ-5682-11A-01D-1535-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.C1233W	0.381	105.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.C1233W (Missense)		KIRC_CONSENSUS2	TCGA-A3-3311-01A-01D-0966-08	TCGA-A3-3311-11A-01D-0966-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.T1202K	0.3579	95.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.T1202K (Missense)		KIRC_CONSENSUS2	TCGA-BP-5186-01A-01D-1429-08	TCGA-BP-5186-11A-01D-1429-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Splice Site	p.X1178_splice	0.4054	37.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.X1178_splice (Splice Site)		KIRC_CONSENSUS2	TCGA-CJ-6033-01A-11D-1669-08	TCGA-CJ-6033-11A-01D-1669-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.P1048R	0.3933	89.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.P1048R (Missense)		KIRC_CONSENSUS2	TCGA-BP-4995-01A-01D-1462-08	TCGA-BP-4995-11A-01D-1462-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.L886R	0.1515	33.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.L886R (Missense)		KIRC_CONSENSUS2	TCGA-A3-3331-01A-01W-0886-08	TCGA-A3-3331-11A-01W-0886-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Deletion	p.K874_I875delinsN	0.2727	44.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.K874_I875delinsN (Deletion)		KIRC_CONSENSUS2	TCGA-B0-5104-01A-01D-1421-08	TCGA-B0-5104-11A-01D-1421-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.Y718C	0.4384	292.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Y718C (Missense)		KIRC_CONSENSUS2	TCGA-BP-5200-01A-01D-1429-08	TCGA-BP-5200-11A-01D-1429-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.I709T	0.527	148.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.I709T (Missense)		KIRC_CONSENSUS2	TCGA-BP-4973-01A-01D-1462-08	TCGA-BP-4973-11A-01D-1462-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.L618H	0.5714	119.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.L618H (Missense)		KIRC_CONSENSUS2	TCGA-CZ-4853-01A-01D-1429-08	TCGA-CZ-4853-11A-01D-1429-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.L614V	0.5258	97.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.L614V (Missense)		KIRC_CONSENSUS2	TCGA-B0-5699-01A-11D-1534-10	TCGA-B0-5699-11A-01D-1534-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.N601K	0.2647	34.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.N601K (Missense)		KIRC_CONSENSUS2	TCGA-BP-4964-01A-01D-1462-08	TCGA-BP-4964-11A-01D-1462-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.I587T	0.52	100.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.I587T (Missense)		KIRC_CONSENSUS2	TCGA-A3-A8OV-01A-11D-A36X-10	TCGA-A3-A8OV-10A-01D-A370-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.M586T	0.551	98.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.M586T (Missense)		KIRC_CONSENSUS2	TCGA-A3-3367-01A-02D-1421-08	TCGA-A3-3367-11A-01D-1421-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.M586K	0.3676	136.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.M586K (Missense)		KIRC_CONSENSUS2	TCGA-B0-5096-01A-01D-1421-08	TCGA-B0-5096-11A-01D-1421-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.A581D	0.2527	91.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.A581D (Missense)		KIRC_CONSENSUS2	TCGA-CJ-4920-01A-01D-1429-08	TCGA-CJ-4920-11A-01D-1429-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.Y580C	0.35	100.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Y580C (Missense)		KIRC_CONSENSUS2	TCGA-B8-4148-01A-02D-1386-10	TCGA-B8-4148-10A-01D-1251-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.N574Y	0.5208	48.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.N574Y (Missense)		KIRC_CONSENSUS2	TCGA-GK-A6C7-01A-11D-A33K-10	TCGA-GK-A6C7-10B-01D-A33K-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Splice Site	p.X434_splice	0.1086	267.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.X434_splice (Splice Site)		KIRC_CONSENSUS2	TCGA-CW-5589-01A-01D-1534-10	TCGA-CW-5589-11A-01D-1535-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Splice Site	p.X332_splice	0.484	188.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.X332_splice (Splice Site)		KIRC_CONSENSUS2	TCGA-B0-5107-01A-01D-1421-08	TCGA-B0-5107-11A-01D-1421-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Splice Site	p.X272_splice	0.1053	38.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.X272_splice (Splice Site)		KIRC_CONSENSUS2	TCGA-B8-5158-01A-01D-1421-08	TCGA-B8-5158-10A-01D-1421-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Splice Site	p.X239_splice	0.2969	384.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.X239_splice (Splice Site)		KIRC_CONSENSUS2	TCGA-B0-5695-01A-11D-1534-10	TCGA-B0-5695-11A-01D-1534-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Splice Site	p.X239_splice	0.3256	86.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.X239_splice (Splice Site)		KIRC_CONSENSUS2	TCGA-CW-6093-01A-11D-1669-08	TCGA-CW-6093-11A-01D-1669-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Splice Site	p.X238_splice	0.3103	145.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.X238_splice (Splice Site)		KIRC_CONSENSUS2	TCGA-A3-3323-01A-01D-0966-08	TCGA-A3-3323-11A-01D-0966-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Splice Site	p.X215_splice	0.2927	82.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.X215_splice (Splice Site)		KIRC_CONSENSUS2	TCGA-B4-5844-01A-11D-1669-08	TCGA-B4-5844-10A-01D-1669-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Splice Site	p.X177_splice	0.269	171.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.X177_splice (Splice Site)		KIRC_CONSENSUS2	TCGA-B4-5377-01A-01D-1501-10	TCGA-B4-5377-10A-01D-1501-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Splice Site	p.X176_splice	0.2981	322.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.X176_splice (Splice Site)		KIRC_CONSENSUS2	TCGA-BP-4801-01A-02D-1421-08	TCGA-BP-4801-11A-01D-1421-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Splice Site	p.X47_splice	0.3333	30.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.X47_splice (Splice Site)		KIRC_CONSENSUS2	TCGA-B8-A54J-01A-11D-A33K-10	TCGA-B8-A54J-10A-01D-A33K-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Splice Site	p.X47_splice	0.5238	84.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.X47_splice (Splice Site)		KIRC_CONSENSUS2	TCGA-BP-5181-01A-01D-1429-08	TCGA-BP-5181-11A-01D-1429-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Splice Site	p.X47_splice	0.4919	124.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.X47_splice (Splice Site)		KIRC_CONSENSUS2	TCGA-CZ-5461-01A-01D-1501-10	TCGA-CZ-5461-11A-01D-1501-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.P42L	0.2639	72.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.P42L (Missense)		KIRC_CONSENSUS2	TCGA-B4-5832-01A-11D-1669-08	TCGA-B4-5832-10A-01D-1669-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.D153Y	0.2099	181.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.D153Y (Missense)	1	KIRC_CONSENSUS2	TCGA-BP-5195-01A-02D-1429-08	TCGA-BP-5195-11A-01D-1429-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.S170N	0.324	250.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.S170N (Missense)	1	KIRC_CONSENSUS2	TCGA-A3-3316-01A-01D-0966-08	TCGA-A3-3316-11A-01D-0966-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.N276K	0.5	102.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.N276K (Missense)	1	KIRC_CONSENSUS2	TCGA-BP-5199-01A-01D-1429-08	TCGA-BP-5199-11A-01D-1429-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Frameshift	p.K767Rfs*23	0.3125	64.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.K767Rfs*23 (Frameshift)		KIRC_CONSENSUS2	TCGA-CW-5589-01A-01D-1534-10	TCGA-CW-5589-11A-01D-1535-10
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Splice Site	p.X516_splice	0.332	241.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.X516_splice (Splice Site)		KIRC_CONSENSUS2	TCGA-B8-5550-01A-01D-1534-10	TCGA-B8-5550-10A-01D-1535-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.G665A	0.2466	73.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.G665A (Missense)		KIRC_CONSENSUS2	TCGA-DV-A4W0-01A-11D-A25V-10	TCGA-DV-A4W0-10A-01D-A25V-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.P1244H	0.3822	157.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P1244H (Missense)		KIRC_CONSENSUS2	TCGA-A3-3320-01A-01D-0966-08	TCGA-A3-3320-11A-01D-0966-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.S1961N	0.2414	58.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.S1961N (Missense)		KIRC_CONSENSUS2	TCGA-B8-5549-01A-01D-1534-10	TCGA-B8-5549-10A-01D-1535-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.I2275T	0.2967	209.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.I2275T (Missense)		KIRC_CONSENSUS2	TCGA-CJ-4912-01A-01D-1429-08	TCGA-CJ-4912-11A-01D-1429-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Frameshift	p.L722Wfs*49	0.2604	96.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.L722Wfs*49 (Frameshift)		KIRC_CONSENSUS2	TCGA-BP-4987-01A-01D-1462-08	TCGA-BP-4987-11A-01D-1462-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Nonsense	p.Y81*	0.0962	104.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.Y81* (Nonsense)		KIRC_CONSENSUS2	TCGA-CZ-4859-01A-02D-1429-08	TCGA-CZ-4859-11A-01D-1429-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.E365Q	0.3409	44.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.E365Q (Missense)		KIRC_CONSENSUS2	TCGA-A3-3322-01A-01D-0966-08	TCGA-A3-3322-11A-01D-0966-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Insertion	p.E386dup	0.2467	150.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.E386dup (Insertion)		KIRC_CONSENSUS2	TCGA-B0-4823-01A-02D-1421-08	TCGA-B0-4823-11A-01D-1421-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.E533D	0.254	63.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.E533D (Missense)		KIRC_CONSENSUS2	TCGA-B4-5377-01A-01D-1501-10	TCGA-B4-5377-10A-01D-1501-10
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.T910M	0.2667	90.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.T910M (Missense)		KIRC_CONSENSUS2	TCGA-A3-A6NI-01A-11D-A33K-10	TCGA-A3-A6NI-10A-01D-A33K-10
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.D1127Y	0.078	205.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.D1127Y (Missense)		KIRC_CONSENSUS2	TCGA-B0-5812-01A-11D-1669-08	TCGA-B0-5812-11A-01D-1669-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.A1186G	0.3412	85.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.A1186G (Missense)		KIRC_CONSENSUS2	TCGA-BP-4992-01A-01D-1462-08	TCGA-BP-4992-11A-01D-1462-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.D1188E	0.1304	92.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.D1188E (Missense)		KIRC_CONSENSUS2	TCGA-B8-A54H-01A-11D-A33K-10	TCGA-B8-A54H-10A-01D-A33K-10
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.A1231T	0.2442	172.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.A1231T (Missense)		KIRC_CONSENSUS2	TCGA-A3-3319-01A-01D-0966-08	TCGA-A3-3319-11A-01D-0966-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.R1243W	0.1111	108.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.R1243W (Missense)		KIRC_CONSENSUS2	TCGA-BP-4964-01A-01D-1462-08	TCGA-BP-4964-11A-01D-1462-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.E1047D	0.3741	139.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.E1047D (Missense)	0	KIRC_CONSENSUS2	TCGA-A3-A8OV-01A-11D-A36X-10	TCGA-A3-A8OV-10A-01D-A370-10
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.L595P	0.1172	128.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.L595P (Missense)	0	KIRC_CONSENSUS2	TCGA-B8-5163-01A-01D-1421-08	TCGA-B8-5163-10A-01D-1421-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Frameshift	p.I1254Sfs*107	0.3196	291.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.I1254Sfs*107 (Frameshift)		KIRC_CONSENSUS2	TCGA-AK-3444-01A-01D-0966-08	TCGA-AK-3444-10A-01D-0966-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Nonsense	p.W265*	0.3333	27.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.W265* (Nonsense)		KIRC_CONSENSUS2	TCGA-BP-4986-01A-01D-1462-08	TCGA-BP-4986-11A-01D-1462-08
Investigate Actionability		Clinical evidence		Somatic Variant	MAP2K2	Deletion	p.E320_L321delinsD	0.1379	58.0	0.0	0.0									Investigate Actionability	Trametinib	MEK inhibition	Targeted therapy	MEK2 Q60P was observed in a patient's trametinib resistant tumor but not pretreatment tumor.	"Wagle, Nikhil, et al. ""MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition."" Cancer discovery 4.1 (2014): 61-68."	https://doi.org/10.1158/2159-8290.CD-13-0631										MAP2K2 p.E320_L321delinsD (Deletion)		KIRC_CONSENSUS2	TCGA-BP-5198-01A-01D-1429-08	TCGA-BP-5198-11A-01D-1429-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.G81D	0.1866	134.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.G81D (Missense)		KIRC_CONSENSUS2	TCGA-B0-5097-01A-01D-1421-08	TCGA-B0-5097-11A-01D-1421-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.L30H	0.2992	127.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.L30H (Missense)		KIRC_CONSENSUS2	TCGA-BP-5178-01A-01D-1429-08	TCGA-BP-5178-11A-01D-1429-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.D29H	0.3333	252.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.D29H (Missense)		KIRC_CONSENSUS2	TCGA-CZ-5456-01A-01D-1501-10	TCGA-CZ-5456-11A-01D-1501-10
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.L117F	0.2732	205.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.L117F (Missense)		KIRC_CONSENSUS2	TCGA-B0-5106-01A-01D-1421-08	TCGA-B0-5106-11A-01D-1421-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.A2000V	0.2989	348.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.A2000V (Missense)		KIRC_CONSENSUS2	TCGA-B0-5098-01A-01D-1421-08	TCGA-B0-5098-11A-01D-1421-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Deletion	p.H1875_L1876del	0.3714	70.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.H1875_L1876del (Deletion)		KIRC_CONSENSUS2	TCGA-CW-6090-01A-11D-1669-08	TCGA-CW-6090-11A-01D-1669-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.N1129Y	0.2114	175.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.N1129Y (Missense)		KIRC_CONSENSUS2	TCGA-B4-5836-01A-11D-1669-08	TCGA-B4-5836-10A-01D-1669-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.L885F	0.1287	101.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.L885F (Missense)		KIRC_CONSENSUS2	TCGA-CJ-4923-01A-01D-1429-08	TCGA-CJ-4923-11A-01D-1429-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.A458V	0.3516	182.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.A458V (Missense)		KIRC_CONSENSUS2	TCGA-B0-5119-01A-02D-1421-08	TCGA-B0-5119-11A-01D-1421-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Nonsense	p.Y318*	0.2989	271.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.Y318* (Nonsense)		KIRC_CONSENSUS2	TCGA-MM-A563-01A-11D-A25V-10	TCGA-MM-A563-10A-01D-A25V-10
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Frameshift	p.R156Efs*28	0.1233	73.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.R156Efs*28 (Frameshift)		KIRC_CONSENSUS2	TCGA-B8-5158-01A-01D-1421-08	TCGA-B8-5158-10A-01D-1421-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.I70L	0.2379	206.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.I70L (Missense)		KIRC_CONSENSUS2	TCGA-BP-5004-01A-01D-1462-08	TCGA-BP-5004-11A-01D-1462-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.S91C	0.4115	192.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.S91C (Missense)		KIRC_CONSENSUS2	TCGA-B0-5701-01A-11D-1534-10	TCGA-B0-5701-11A-01D-1534-10
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.R1541T	0.1351	333.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.R1541T (Missense)		KIRC_CONSENSUS2	TCGA-B0-5108-01A-01D-1421-08	TCGA-B0-5108-11A-01D-1421-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.I201M	0.2167	646.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.I201M (Missense)		KIRC_CONSENSUS2	TCGA-CJ-4916-01A-01D-1429-08	TCGA-CJ-4916-11A-01D-1429-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.R216Q	0.3393	224.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.R216Q (Missense)		KIRC_CONSENSUS2	TCGA-BP-5010-01A-02D-1421-08	TCGA-BP-5010-11A-01D-1421-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.I312L	0.1948	462.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.I312L (Missense)		KIRC_CONSENSUS2	TCGA-CZ-4859-01A-02D-1429-08	TCGA-CZ-4859-11A-01D-1429-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.R667W	0.1515	231.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.R667W (Missense)		KIRC_CONSENSUS2	TCGA-B0-5709-01A-11D-1534-10	TCGA-B0-5709-11A-01D-1534-10
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.T125P	0.112	125.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.T125P (Missense)		KIRC_CONSENSUS2	TCGA-CJ-4923-01A-01D-1429-08	TCGA-CJ-4923-11A-01D-1429-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.T150I	0.2378	286.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.T150I (Missense)		KIRC_CONSENSUS2	TCGA-CW-5588-01A-01D-1534-10	TCGA-CW-5588-11A-01D-1535-10
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.E279K	0.3258	178.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.E279K (Missense)		KIRC_CONSENSUS2	TCGA-CZ-4853-01A-01D-1429-08	TCGA-CZ-4853-11A-01D-1429-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.K535Q	0.2784	97.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.K535Q (Missense)		KIRC_CONSENSUS2	TCGA-B0-5710-01A-11D-1669-08	TCGA-B0-5710-11A-01D-1669-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.H1140Q	0.2051	156.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.H1140Q (Missense)		KIRC_CONSENSUS2	TCGA-B8-4622-01A-02D-1553-08	TCGA-B8-4622-11A-01D-1553-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.N426D	0.4541	196.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.N426D (Missense)		KIRC_CONSENSUS2	TCGA-BP-4973-01A-01D-1462-08	TCGA-BP-4973-11A-01D-1462-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Nonsense	p.E1097*	0.2959	419.0	0.0	0.0																Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK2 p.E1097* (Nonsense)		KIRC_CONSENSUS2	TCGA-CJ-5676-01A-11D-1534-10	TCGA-CJ-5676-11A-01D-1534-10
Biologically Relevant				Somatic Variant	MTOR	Missense	p.I2500M	0.2153	144.0	0.0	0.0																									MTOR p.I2500M (Missense)		KIRC_CONSENSUS2	TCGA-CW-5580-01A-01D-1669-08	TCGA-CW-5580-11A-02D-1669-08
Biologically Relevant				Somatic Variant	MTOR	Deletion	p.R2430_L2431del	0.1053	114.0	0.0	0.0																									MTOR p.R2430_L2431del (Deletion)		KIRC_CONSENSUS2	TCGA-CJ-4907-01A-01D-1429-08	TCGA-CJ-4907-11A-01D-1429-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.V2422I	0.3871	93.0	0.0	0.0																									MTOR p.V2422I (Missense)		KIRC_CONSENSUS2	TCGA-B0-5712-01A-11D-1669-08	TCGA-B0-5712-11A-01D-1669-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.V2406M	0.3023	86.0	0.0	0.0																									MTOR p.V2406M (Missense)		KIRC_CONSENSUS2	TCGA-A3-A8OU-01A-11D-A36X-10	TCGA-A3-A8OU-10A-01D-A370-10
Biologically Relevant				Somatic Variant	MTOR	Missense	p.L2334V	0.1275	408.0	0.0	0.0																									MTOR p.L2334V (Missense)		KIRC_CONSENSUS2	TCGA-B0-5691-01A-11D-1534-10	TCGA-B0-5691-11A-01D-1534-10
Biologically Relevant				Somatic Variant	MTOR	Missense	p.I2228T	0.4615	39.0	0.0	0.0																									MTOR p.I2228T (Missense)		KIRC_CONSENSUS2	TCGA-B0-5098-01A-01D-1421-08	TCGA-B0-5098-11A-01D-1421-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.S2215Y	0.6087	207.0	0.0	0.0																									MTOR p.S2215Y (Missense)		KIRC_CONSENSUS2	TCGA-CJ-5679-01A-11D-1534-10	TCGA-CJ-5679-11A-01D-1535-10
Biologically Relevant				Somatic Variant	MTOR	Missense	p.T1977R	0.2514	183.0	0.0	0.0																									MTOR p.T1977R (Missense)		KIRC_CONSENSUS2	TCGA-B4-5832-01A-11D-1669-08	TCGA-B4-5832-10A-01D-1669-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.T1977R	0.2336	214.0	0.0	0.0																									MTOR p.T1977R (Missense)		KIRC_CONSENSUS2	TCGA-B4-5844-01A-11D-1669-08	TCGA-B4-5844-10A-01D-1669-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.T1977K	0.3459	266.0	0.0	0.0																									MTOR p.T1977K (Missense)		KIRC_CONSENSUS2	TCGA-B0-4827-01A-02D-1421-08	TCGA-B0-4827-11A-01D-1421-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.I1973F	0.1481	189.0	0.0	0.0																									MTOR p.I1973F (Missense)		KIRC_CONSENSUS2	TCGA-B0-5100-01A-01D-1421-08	TCGA-B0-5100-11A-01D-1421-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.F1888L	0.4954	109.0	0.0	0.0																									MTOR p.F1888L (Missense)		KIRC_CONSENSUS2	TCGA-CZ-4866-01A-01D-1501-10	TCGA-CZ-4866-11A-01D-1501-10
Biologically Relevant				Somatic Variant	MTOR	Missense	p.A1519T	0.2105	57.0	0.0	0.0																									MTOR p.A1519T (Missense)		KIRC_CONSENSUS2	TCGA-CJ-6027-01A-11D-1669-08	TCGA-CJ-6027-11A-01D-1669-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.C1483F	0.0371	377.0	0.0	0.0																									MTOR p.C1483F (Missense)		KIRC_CONSENSUS2	TCGA-CJ-4907-01A-01D-1429-08	TCGA-CJ-4907-11A-01D-1429-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.C1483Y	0.2308	104.0	0.0	0.0																									MTOR p.C1483Y (Missense)		KIRC_CONSENSUS2	TCGA-B0-5696-01A-11D-1534-10	TCGA-B0-5696-11A-01D-1534-10
Biologically Relevant				Somatic Variant	MTOR	Missense	p.Y1463S	0.1849	146.0	0.0	0.0																									MTOR p.Y1463S (Missense)		KIRC_CONSENSUS2	TCGA-B0-5697-01A-11D-1534-10	TCGA-B0-5697-11A-01D-1534-10
Biologically Relevant				Somatic Variant	MTOR	Missense	p.L1460P	0.3818	110.0	0.0	0.0																									MTOR p.L1460P (Missense)		KIRC_CONSENSUS2	TCGA-B0-5701-01A-11D-1534-10	TCGA-B0-5701-11A-01D-1534-10
Biologically Relevant				Somatic Variant	MTOR	Missense	p.L1460P	0.303	198.0	0.0	0.0																									MTOR p.L1460P (Missense)		KIRC_CONSENSUS2	TCGA-BP-5175-01A-01D-1429-08	TCGA-BP-5175-11A-01D-1429-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.A1459P	0.2207	213.0	0.0	0.0																									MTOR p.A1459P (Missense)		KIRC_CONSENSUS2	TCGA-BP-5176-01A-01D-1429-08	TCGA-BP-5176-11A-01D-1429-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.K1452N	0.3015	136.0	0.0	0.0																									MTOR p.K1452N (Missense)		KIRC_CONSENSUS2	TCGA-CZ-5987-01A-11D-1669-08	TCGA-CZ-5987-11A-01D-1669-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.L1433S	0.2646	223.0	0.0	0.0																									MTOR p.L1433S (Missense)		KIRC_CONSENSUS2	TCGA-BP-5001-01A-01D-1462-08	TCGA-BP-5001-11A-01D-1462-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.K860N	0.0345	232.0	0.0	0.0																									MTOR p.K860N (Missense)		KIRC_CONSENSUS2	TCGA-B0-5119-01A-02D-1421-08	TCGA-B0-5119-11A-01D-1421-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.R755C	0.2778	72.0	0.0	0.0																									MTOR p.R755C (Missense)		KIRC_CONSENSUS2	TCGA-MM-A84U-01A-11D-A36X-10	TCGA-MM-A84U-10A-01D-A370-10
Biologically Relevant				Somatic Variant	MTOR	Missense	p.E367V	0.3143	35.0	0.0	0.0																									MTOR p.E367V (Missense)		KIRC_CONSENSUS2	TCGA-MM-A564-01A-11D-A25V-10	TCGA-MM-A564-10A-01D-A25V-10
Biologically Relevant				Somatic Variant	CDKN2C	Missense	p.R39T	0.3017	232.0	0.0	0.0																									CDKN2C p.R39T (Missense)		KIRC_CONSENSUS2	TCGA-CZ-5451-01A-01D-1501-10	TCGA-CZ-5451-11A-01D-1501-10
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.L127V	0.1119	143.0	0.0	0.0																									NTRK1 p.L127V (Missense)		KIRC_CONSENSUS2	TCGA-CJ-4869-01A-02D-1429-08	TCGA-CJ-4869-11A-01D-1429-08
Biologically Relevant				Somatic Variant	NTRK1	Frameshift	p.L466Cfs*4	0.2656	128.0	0.0	0.0																									NTRK1 p.L466Cfs*4 (Frameshift)		KIRC_CONSENSUS2	TCGA-B0-5108-01A-01D-1421-08	TCGA-B0-5108-11A-01D-1421-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.H489Q	0.2824	85.0	0.0	0.0																									NTRK1 p.H489Q (Missense)		KIRC_CONSENSUS2	TCGA-DV-5576-01A-01D-1534-10	TCGA-DV-5576-10A-01D-1535-10
Biologically Relevant				Somatic Variant	SLC45A3	Frameshift	p.P435Lfs*107	0.1538	52.0	0.0	0.0																									SLC45A3 p.P435Lfs*107 (Frameshift)		KIRC_CONSENSUS2	TCGA-A3-3376-01A-02D-1421-08	TCGA-A3-3376-11A-01D-1421-08
Biologically Relevant				Somatic Variant	SLC45A3	Missense	p.V276M	0.3571	42.0	0.0	0.0																									SLC45A3 p.V276M (Missense)		KIRC_CONSENSUS2	TCGA-BP-4976-01A-01D-1462-08	TCGA-BP-4976-11A-01D-1462-08
Biologically Relevant				Somatic Variant	FLI1	Missense	p.E303K	0.4615	13.0	0.0	0.0																									FLI1 p.E303K (Missense)		KIRC_CONSENSUS2	TCGA-B4-5838-01A-11D-1669-08	TCGA-B4-5838-10A-01D-1669-08
Biologically Relevant				Somatic Variant	RB1	Missense	p.V654M	0.5364	110.0	0.0	0.0																									RB1 p.V654M (Missense)		KIRC_CONSENSUS2	TCGA-BP-4770-01A-01D-1501-10	TCGA-BP-4770-11A-01D-1501-10
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.R735H	0.1739	69.0	0.0	0.0																									NTRK3 p.R735H (Missense)		KIRC_CONSENSUS2	TCGA-CZ-5461-01A-01D-1501-10	TCGA-CZ-5461-11A-01D-1501-10
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.D609N	0.2105	57.0	0.0	0.0																									NTRK3 p.D609N (Missense)		KIRC_CONSENSUS2	TCGA-B8-4148-01A-02D-1386-10	TCGA-B8-4148-10A-01D-1251-10
Biologically Relevant				Somatic Variant	NF1	Missense	p.S856N	0.2941	102.0	0.0	0.0																									NF1 p.S856N (Missense)		KIRC_CONSENSUS2	TCGA-B0-5098-01A-01D-1421-08	TCGA-B0-5098-11A-01D-1421-08
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.R1534Hfs*40	0.367	109.0	0.0	0.0																									NF1 p.R1534Hfs*40 (Frameshift)		KIRC_CONSENSUS2	TCGA-A3-A6NN-01A-12D-A33K-10	TCGA-A3-A6NN-10A-01D-A33K-10
Biologically Relevant				Somatic Variant	NF1	Missense	p.L2209S	0.3318	214.0	0.0	0.0																									NF1 p.L2209S (Missense)		KIRC_CONSENSUS2	TCGA-CZ-4853-01A-01D-1429-08	TCGA-CZ-4853-11A-01D-1429-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.K2595E	0.262	397.0	0.0	0.0																									NF1 p.K2595E (Missense)		KIRC_CONSENSUS2	TCGA-BP-5176-01A-01D-1429-08	TCGA-BP-5176-11A-01D-1429-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Y2742*	0.3826	230.0	0.0	0.0																									NF1 p.Y2742* (Nonsense)		KIRC_CONSENSUS2	TCGA-A3-3382-01A-01D-0966-08	TCGA-A3-3382-11A-01D-0966-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.G2745*	0.2579	221.0	0.0	0.0																									NF1 p.G2745* (Nonsense)		KIRC_CONSENSUS2	TCGA-B0-5710-01A-11D-1669-08	TCGA-B0-5710-11A-01D-1669-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.G422S	0.2703	37.0	0.0	0.0																									COL1A1 p.G422S (Missense)		KIRC_CONSENSUS2	TCGA-B0-5088-01A-01D-1462-08	TCGA-B0-5088-11A-01D-1462-08
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.M409T	0.381	21.0	0.0	0.0																									KEAP1 p.M409T (Missense)		KIRC_CONSENSUS2	TCGA-BP-5183-01A-01D-1429-08	TCGA-BP-5183-11A-01D-1429-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.I233N	0.3824	68.0	0.0	0.0																									BRD4 p.I233N (Missense)		KIRC_CONSENSUS2	TCGA-CZ-5453-01A-01D-1501-10	TCGA-CZ-5453-11A-01D-1501-10
Biologically Relevant				Somatic Variant	EML4	Nonsense	p.S29*	0.1493	134.0	0.0	0.0																									EML4 p.S29* (Nonsense)		KIRC_CONSENSUS2	TCGA-CJ-4918-01A-01D-1429-08	TCGA-CJ-4918-11A-01D-1429-08
Biologically Relevant				Somatic Variant	TPX2	Missense	p.E280A	0.0762	223.0	0.0	0.0																									TPX2 p.E280A (Missense)		KIRC_CONSENSUS2	TCGA-BP-5169-01A-01D-1429-08	TCGA-BP-5169-11A-01D-1429-08
Biologically Relevant				Somatic Variant	TPX2	Missense	p.K641Q	0.0909	88.0	0.0	0.0																									TPX2 p.K641Q (Missense)		KIRC_CONSENSUS2	TCGA-A3-A8OW-01A-11D-A36X-10	TCGA-A3-A8OW-10A-01D-A370-10
Biologically Relevant				Somatic Variant	TPX2	Frameshift	p.E658Dfs*24	0.2929	99.0	0.0	0.0																									TPX2 p.E658Dfs*24 (Frameshift)		KIRC_CONSENSUS2	TCGA-MM-A84U-01A-11D-A36X-10	TCGA-MM-A84U-10A-01D-A370-10
Biologically Relevant				Somatic Variant	ERG	Nonsense	p.Y201*	0.4605	152.0	0.0	0.0																									ERG p.Y201* (Nonsense)		KIRC_CONSENSUS2	TCGA-B8-A54K-01A-11D-A33K-10	TCGA-B8-A54K-10A-01D-A33K-10
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.P424L	0.1655	139.0	0.0	0.0																									LIMK2 p.P424L (Missense)		KIRC_CONSENSUS2	TCGA-B0-4945-01A-01D-1421-08	TCGA-B0-4945-11A-01D-1421-08
Biologically Relevant				Somatic Variant	MLH1	Missense	p.I500L	0.4198	262.0	0.0	0.0																									MLH1 p.I500L (Missense)		KIRC_CONSENSUS2	TCGA-B0-5098-01A-01D-1421-08	TCGA-B0-5098-11A-01D-1421-08
Biologically Relevant				Somatic Variant	FIP1L1	Frameshift	p.D156Efs*50	0.3146	178.0	0.0	0.0																									FIP1L1 p.D156Efs*50 (Frameshift)		KIRC_CONSENSUS2	TCGA-A3-3357-01A-02D-1421-08	TCGA-A3-3357-11A-01D-1421-08
Biologically Relevant				Somatic Variant	FIP1L1	Missense	p.S262P	0.2231	121.0	0.0	0.0																									FIP1L1 p.S262P (Missense)		KIRC_CONSENSUS2	TCGA-B0-5812-01A-11D-1669-08	TCGA-B0-5812-11A-01D-1669-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E2308Q	0.2887	142.0	0.0	0.0																									ROS1 p.E2308Q (Missense)		KIRC_CONSENSUS2	TCGA-B2-5633-01A-01D-A270-10	TCGA-B2-5633-10A-01D-A270-10
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E1905D	0.2921	89.0	0.0	0.0																									ROS1 p.E1905D (Missense)		KIRC_CONSENSUS2	TCGA-A3-A6NI-01A-11D-A33K-10	TCGA-A3-A6NI-10A-01D-A33K-10
Biologically Relevant				Somatic Variant	ROS1	Missense	p.V1557I	0.1818	88.0	0.0	0.0																									ROS1 p.V1557I (Missense)		KIRC_CONSENSUS2	TCGA-B2-4102-01A-02D-1386-10	TCGA-B2-4102-11A-01D-1251-10
Biologically Relevant				Somatic Variant	ROS1	Missense	p.D1512N	0.3	310.0	0.0	0.0																									ROS1 p.D1512N (Missense)		KIRC_CONSENSUS2	TCGA-B0-5700-01A-11D-1534-10	TCGA-B0-5700-11A-01D-1534-10
Biologically Relevant				Somatic Variant	ROS1	Splice Site	p.X1441_splice	0.2706	255.0	0.0	0.0																									ROS1 p.X1441_splice (Splice Site)		KIRC_CONSENSUS2	TCGA-A3-3387-01A-01D-1534-10	TCGA-A3-3387-11A-01D-1534-10
Biologically Relevant				Somatic Variant	ROS1	Missense	p.P1350Q	0.1814	226.0	0.0	0.0																									ROS1 p.P1350Q (Missense)		KIRC_CONSENSUS2	TCGA-B0-4827-01A-02D-1421-08	TCGA-B0-4827-11A-01D-1421-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.Y800C	0.3711	97.0	0.0	0.0																									ROS1 p.Y800C (Missense)		KIRC_CONSENSUS2	TCGA-G6-A8L7-01A-11D-A36X-10	TCGA-G6-A8L7-10A-01D-A370-10
Biologically Relevant				Somatic Variant	ROS1	Missense	p.D780E	0.2131	244.0	0.0	0.0																									ROS1 p.D780E (Missense)		KIRC_CONSENSUS2	TCGA-CJ-4869-01A-02D-1429-08	TCGA-CJ-4869-11A-01D-1429-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.T243K	0.1051	552.0	0.0	0.0																									ROS1 p.T243K (Missense)		KIRC_CONSENSUS2	TCGA-B8-5550-01A-01D-1534-10	TCGA-B8-5550-10A-01D-1535-10
Biologically Relevant				Somatic Variant	ROS1	Missense	p.L232V	0.2198	91.0	0.0	0.0																									ROS1 p.L232V (Missense)		KIRC_CONSENSUS2	TCGA-B8-A54J-01A-11D-A33K-10	TCGA-B8-A54J-10A-01D-A33K-10
Biologically Relevant				Somatic Variant	PMS2	Missense	p.G361R	0.237	173.0	0.0	0.0																									PMS2 p.G361R (Missense)		KIRC_CONSENSUS2	TCGA-AK-3444-01A-01D-0966-08	TCGA-AK-3444-10A-01D-0966-08
Biologically Relevant				Somatic Variant	POT1	Splice Site	p.X182_splice	0.3162	136.0	0.0	0.0																									POT1 p.X182_splice (Splice Site)		KIRC_CONSENSUS2	TCGA-CZ-5453-01A-01D-1501-10	TCGA-CZ-5453-11A-01D-1501-10
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.V629L	0.2949	78.0	0.0	0.0																									FGFR1 p.V629L (Missense)		KIRC_CONSENSUS2	TCGA-CW-6090-01A-11D-1669-08	TCGA-CW-6090-11A-01D-1669-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.A263S	0.1946	149.0	0.0	0.0																									FGFR1 p.A263S (Missense)		KIRC_CONSENSUS2	TCGA-CJ-6031-01A-11D-1669-08	TCGA-CJ-6031-11A-01D-1669-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.W10C	0.2955	88.0	0.0	0.0																									FGFR1 p.W10C (Missense)		KIRC_CONSENSUS2	TCGA-A3-3385-01A-02D-1421-08	TCGA-A3-3385-11A-01D-1421-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.V328L	0.1011	89.0	0.0	0.0																									ESRP1 p.V328L (Missense)		KIRC_CONSENSUS2	TCGA-B0-5095-01A-01D-1421-08	TCGA-B0-5095-11A-01D-1421-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.V684I	0.25	72.0	0.0	0.0																									NTRK2 p.V684I (Missense)		KIRC_CONSENSUS2	TCGA-G6-A5PC-01A-11D-A33K-10	TCGA-G6-A5PC-10A-01D-A33K-10
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.S1549Hfs*15 (Frameshift), JAK1 p.L722Wfs*49 (Frameshift), JAK1 p.Y81* (Nonsense), POLE p.I1254Sfs*107 (Frameshift), DOCK3 p.N1302Rfs*23 (Frameshift)																													Supporting variants: PRDM2 p.S1549Hfs*15 (Frameshift), JAK1 p.L722Wfs*49 (Frameshift), JAK1 p.Y81* (Nonsense), POLE p.I1254Sfs*107 (Frameshift), DOCK3 p.N1302Rfs*23 (Frameshift)		KIRC_CONSENSUS2		
Biologically Relevant				Mutational Signature	COSMIC Signature 9	version 2	0.426																													COSMIC Signature (version 2) 9 (43%)		KIRC_CONSENSUS2		
Biologically Relevant				Mutational Signature	COSMIC Signature 25	version 2	0.356																													COSMIC Signature (version 2) 25 (36%)		KIRC_CONSENSUS2		
